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SUMMARY 12 
 13 
Infections caused by protozoan parasites are among the most widespread and intractable transmissible 14 
diseases affecting the developing world, with malaria and leishmaniasis being most costly in terms of 15 
morbidity and mortality. Although new drugs are urgently required against both diseases in the face of 16 
ever-rising resistance to frontline therapies, very few candidates passing through development 17 
pipelines possess a known and novel mode of action. Set in the context of drugs currently in use and 18 
under development, we present the evidence for N-myristoyltransferase (NMT), an enzyme that N-19 
terminally lipidates a wide range of specific target proteins through post-translational modification, as 20 
a potential drug target in malaria and the leishmaniases. We discuss the limitations of current 21 
knowledge regarding the downstream targets of this enzyme in protozoa, and our recent progress 22 
towards potent cell-active NMT inhibitors against the most clinically-relevant species of parasite. 23 
Finally, we outline the next steps required in terms of both tools to understand N-myristoylation in 24 
protozoan parasites, and the generation of potential development candidates based on the output of 25 
our recently-reported high-throughput screens. 26 
INTRODUCTION 27 
Malaria 28 
Malaria is a disease caused by infection of a human host with protozoan parasites of the genus 29 
Plasmodium, and is a devastating global health issue with approximately 200 million cases and 30 
1 million deaths in 2010 alone (Murray et al. 2012). The complex life cycle of malaria parasites 31 
spreads across two hosts and five host tissues whilst undergoing at least ten distinct morphological 32 
transitions (Sturm et al. 2006; Mackinnon and Marsh 2010). Replication of parasites and subsequent 33 
rupture of erythrocytes in the intra-erythrocytic stages are responsible for the clinical symptoms of 34 
malaria, and the majority of drugs target these asexual (human-host) stages of the life cycle. Some 35 
species of malaria, most notably Plasmodium vivax, can exist in a latent liver hypnozoite form that 36 
can cause relapse even after clearance of bloodstream parasites (Derbyshire et al. 2012; Rodrigues et 37 
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al. 2012). Of the five relevant species of human parasite, the vast majority of deaths occur from P. 38 
falciparum infections, which is the typical cause of severe malaria (Claessens et al. 2012). This has 39 
led to the majority of drug discovery efforts focussing on P. falciparum, typically at the expense of 40 
other species. Although the demand for new P. falciparum drugs is in no doubt, P. vivax is 41 
responsible for the majority of worldwide malaria endemicity (Price et al. 2009; WHO 2011). 42 
However, difficulties culturing the parasite (Udomsangpetch et al. 2007) along with challenges 43 
imaging and targeting the hypnozoite liver stages (Meister et al. 2011) have led to a dearth of new P. 44 
vivax drugs (Price et al. 2009). Medications capable of targeting all relevant species of parasite, and 45 
crucially clearing liver-stage parasites, are in great demand. 46 
For the latter half of the 20th century, antimalarial drug discovery was a success story for natural 47 
product-inspired therapies, by far the most widely used of which are chloroquine (Loeb et al. 1946) 48 
and artemisinin (Miller and Su 2011). 49 
Chloroquine was first discovered as a derivative of antimalarial natural product quinine (Krafts et al. 50 
2012), and has been a first-line antimalarial for over sixty years (Loeb et al. 1946). Studies over the 51 
past twenty years have shown that this class of compounds (with the exception of primaquine) is 52 
involved in the disruption of haem detoxification by the parasite (Weissbuch and Leiserowitz 2008). 53 
Artemisinin is a highly effective antimalarial natural product, isolated from Artemisia annua (Miller 54 
and Su 2011); its antimalarial action is still under debate, but most hypotheses involve reductive 55 
activation of the endoperoxide moiety resulting in parasite death from oxidative damage (O'Neill and 56 
Posner 2004; Li and Zhou 2010; Slack et al. 2012). Other drug classes used in the treatment of 57 
malaria to varying extents include pyrimidine biosynthesis disruptors, drugs that target the apicoplast 58 
(Botté et al. 2012) and drugs discovered by phenotypic screening with unknown targets (e.g. 59 
primaquine) (Kappe et al. 2010). Despite the apparent plethora of antimalarials, drug resistance is a 60 
major issue and new medications with distinct mechanisms are constantly required to combat the 61 
continued evolution of the parasite (Fidock 2010; Mackinnon and Marsh 2010). This is compounded 62 
by the emergence of resistance to the artemisinins in Asia, (Dondorp et al. 2009; Phyo et al. 2012) 63 
reinforcing the urgent requirement for new therapies. Fortunately, a great deal of resource has been 64 
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directed towards antimalarial drug discovery in the past few decades. Elaboration of the artemisinin 65 
pharmacophore has resulted in multiple clinical candidates (Vennerstrom et al. 2004; O'Neill et al. 66 
2010; Charman et al. 2011), although the potential effectiveness of these compounds in artemisinin-67 
resistant regions remains a concern due to the shared mechanism of action. In addition, novel 68 
inhibitors of the pyrimidine biosynthetic pathway are in development (Painter et al. 2007) and 69 
phenotypic high-throughput screens have resulted in a wealth of information on relevant scaffolds 70 
(Plouffe et al. 2008; Gamo et al. 2010; Guiguemde et al. 2010), and yielded promising clinical 71 
candidates (Rottmann et al. 2010). Among the numerous clinical and preclinical candidates for the 72 
treatment for malaria, the vast majority work by existing or unknown mechanisms and are based on 73 
known pharmacophores; indeed many are new combinations of existing marketed drugs. Although 74 
some have shown efficacy against resistant strains, concerns remain that resistance may develop 75 
quickly against already vulnerable mechanisms. New drugs that work by distinct novel biological 76 
mechanisms are therefore highly desirable.  77 
The leishmaniases 78 
The leishmaniases are the second most prevalent class of parasitic infection after malaria, giving rise 79 
to >2 million new cases each year. The disease occurs in three forms, cutaneous (CL), muco-80 
cutaneous (MCL) and the most fatal form, visceral leishmaniasis (VL). The latter is associated with 81 
infection by the species Leishmania donovani, while the cutaneous forms are due to infection by 82 
multiple species including L. major, L. braziliensis and L. mexicana.  The leishmaniases are endemic 83 
in more than 90 countries around the world, being particularly prevalent in India, East Africa, 84 
Bangladesh and Brazil. Additional clinical issues include post-kala-azar dermal leishmaniasis 85 
(PKDL), occurring after the apparent drug cure of VL in certain geographical regions (e.g. Sudan) and 86 
difficult to cure with pentavalent antimonials. Combination therapies with therapeutic vaccines 87 
(Maroof et al. 2012) or immune-response activating drugs, such as imiquimod (Arevalo et al. 2001), 88 
show some promise. In contrast to the wealth of treatments and drugs in development for malaria, the 89 
leishmaniases are poorly provided for. None of the currently available drugs (Fig. 2) were discovered 90 
by a rational design process for this neglected disease, and suffer from drawbacks including lack of an 91 
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oral formulation, prolonged treatment times, high cost of treatment, toxicity, teratogenicity and/or 92 
increasing drug resistance.  In addition, all work through unknown mechanisms, by disruption of cell 93 
membranes or through unspecific antibiotic effects. There are very few drugs in development for 94 
these conditions with the most advanced being another antibiotic, fexinidazole (Winkelmann and 95 
Raether 1978), discovered as part of a repurposing initiative (Wyllie et al. 2012).  96 
PROTEIN N-MYRISTOYLTRANSFERASE 97 
The post-translational modification (PTM) of proteins contributes hugely to the chemical and 98 
functional diversity of the cellular proteome and results in the incorporation of molecular motifs not 99 
directly encoded by the genome. Protein N-myristoylation is the attachment of a 14-carbon saturated 100 
fatty acid, myristate, to the N-terminal glycine residue in a specific set of cellular proteins, catalysed 101 
by the enzyme myristoyl CoA:Protein N-myristoyltransferase, NMT (Fig. 3) (Wright et al. 2010). 102 
Whilst N-myristoylation is often referred to as a PTM, it most commonly occurs co-translationally. 103 
Post-translational myristoylation is less well documented but is known to occur following exposure of 104 
an internal glycine after cleavage of proteins by caspases during the apoptotic cascade (Zha et al. 105 
2000). N-Myristoylation can be involved in protein stability, protein-protein interaction interfaces and 106 
association of proteins with membranes. 107 
NMT appears to be ubiquitous in eukaryotes, including fungi (Towler et al. 1987; Lodge et al. 1994; 108 
Shaw et al. 2002), insects (Ntwasa et al. 1997), plants (Boisson et al. 2003), mammals (including 109 
mouse, rat, cow and human) and the parasitic protozoa P. falciparum (Gunaratne et al. 2000), L. 110 
major (Price et al. 2003), L. donovani (Brannigan et al. 2010) and Trypanosoma brucei (Price et al. 111 
2003). NMT has been shown to be essential for survival in the bloodstream form of T. brucei (Price et 112 
al. 2003; Price et al. 2010), in insect stages of L. major (Price et al. 2003) and L. donovani (Brannigan 113 
et al. 2010) and most recently in the rodent malaria parasite P. berghei (Pino et al. 2012). 114 
NMT structure and mechanism 115 
The enzyme catalytic cycle has been well-studied in yeast, and follows a Bi-Bi mechanism (Towler et 116 
al. 1987; Rudnick et al. 1991). Myristoyl-CoA (Myr-CoA) binds to the apo-enzyme, inducing a 117 
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conformational change that allows the protein substrate to bind. Myristate is transferred by attack of 118 
the N-terminal glycine amine of the peptide on the thioester carbonyl of Myr-CoA (Rudnick et al. 119 
1991); CoA is released followed by the myristoylated substrate. The first crystal structure of an NMT 120 
to be published was Candida albicans NMT (CaNMT) (Weston et al. 1998). Crystal structures of 121 
Saccharomyces cerevisiae) (ScNMT) (Bhatnagar et al. 1998; Farazi et al. 2001b), and more recently 122 
Leishmania donovani NMT, (LdNMT) (Brannigan et al. 2010), L. major, (LmNMT) (Frearson et al. 123 
2010), and the P. vivax enzyme (Goncalves et al. 2012b), followed. These structures and others 124 
provide insight into the binding sites of Myr-CoA, peptide substrates and inhibitors. Published 125 
structures are consistent with a highly conserved Myr-CoA binding mode, with Myr-CoA binding in a 126 
bent ‘question mark’ conformation (Fig. 4b). The thioester carbonyl is placed into an ‘oxyanion hole’, 127 
which activates it for nucleophilic attack, and the fatty acyl chain of Myr-CoA inserts into a deep, 128 
hydrophobic pocket. The peptide N-terminal glycine ammonium interacts electrostatically with the 129 
buried carboxylate of the C-terminal enzyme residue (Farazi et al. 2001b), which is responsible for 130 
deprotonation of the ammonium so that the generated nucleophilic amine can attack the Myr-CoA 131 
thioester (Farazi et al. 2001a; Farazi et al. 2001b).  132 
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NMT substrate specificity 133 
NMT appears to be highly specific for transfer of C14 fatty acid, tolerating only slight changes to 134 
chain length (reviewed in (Wright et al. 2010)). However, peptide substrate specificity is complex and 135 
there is no definitive “myristoylation motif”, beyond the requirement for an N-terminal glycine. This 136 
requirement may be mechanism-based: Gordon and co-workers have suggested that rotation of the 137 
peptide N-terminal amine about the peptide backbone aligns it for attack on the thioester, and that 138 
such a rotation may be hindered for residues with β-substituents, i.e. any amino acid except for 139 
glycine (Farazi et al. 2001b). Maurer-Stroh and co-workers used crystal structures and biochemical 140 
data to develop a myristoylation predictive tool: the MYR predictor (Maurer-Stroh et al. 2002a; 141 
Maurer-Stroh et al. 2002b), which suggested that as many as 17 residues may be involved in substrate 142 
recognition by NMT. A second tool for predicting N-myristoylation, the Myristoylator, is based upon 143 
a different model for prediction (neural networks, or machine learning) but generates similar error 144 
rates compared to the MYR predictor (Bologna et al. 2004). Both predictors are necessarily based on 145 
the set of proteins annotated or predicted to be N-myristoylated using sequence similarity in 146 
SwissProt. Unlike the acyl-CoA binding site, the peptide pocket is not well conserved across NMTs 147 
from different species (Maurer-Stroh et al. 2002b). This, together with the observation that NMT is 148 
essential for survival, means that this pocket is a target for selective NMT inhibitors 149 
(Georgopapadakou 2002; Price et al. 2003). 150 
PROTEIN N-MYRISTOYLATION 151 
Myristoylated proteins have been estimated to make up between 0.5 % and 3 % of eukaryotic cellular 152 
proteomes, depending on the species and in silico model used (Maurer-Stroh et al. 2002a; Martinez et 153 
al. 2008). In the majority of myristoylated proteins studied so far, myristate has a role in transient 154 
membrane localisation. The ‘two-signal’ membrane binding model suggests that strong membrane 155 
localisation is only achieved when a second feature of the protein complements myristoylation (Resh 156 
1994). This may be a second acyl group near the N-terminus, such as palmitate (which is usually 157 
attached to the side-chain of cysteine residues), a polybasic cluster of amino acids that interacts with 158 
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membrane phospholipid acidic head groups, or a domain that interacts with another membrane-bound 159 
protein (Resh 2006a). Membrane binding in some myristoylated proteins is dynamically regulated via 160 
so-called myristoyl-switches, as in the ARF-GTPases, where a change in the ligand bound (from GTP 161 
to GDP) causes a conformational change that exposes a hydrophobic pocket that binds myristate, 162 
sequestering the fatty acyl chain so that it can no longer interact with the membrane bilayer (Goldberg 163 
1998). Myristate-mediated membrane binding is clearly an important mechanism and numerous 164 
studies have concluded that it often contributes to the function or regulation of the target protein. 165 
Detecting N-myristoylation in protozoan parasites 166 
Predicting and validating the N-myristoylation of potential substrate proteins in general is challenging 167 
due to the complex substrate specificity of NMT and difficulties inherent in detecting protein 168 
lipidation. Some proteins can be assigned as likely NMT substrates based on homology; an example 169 
being the ARF-GTPases, a class of proteins present in all eukaryotes, having common roles and 170 
known to be N-myristoylated in many organisms (Donaldson and Jackson 2011). For protozoan 171 
parasite proteins sharing no sequence identity with generic eukaryotic proteins the main recourse is 172 
bioinformatic prediction. However, these tools are necessarily based on known N-myristoylated 173 
proteins, of which few have been reported in protozoan parasites, and many of these predictions still 174 
require experimental proof. Demonstrating N-myristoylation of a protein in its native context is non-175 
trivial, and thus non-native approaches predominate. A candidate protein is often over-expressed as a 176 
GFP or other tagged construct, or the protein of interest is co-expressed with NMT in E. coli, and 177 
metabolic radiolabelling with myristate or mass spectrometry is used to demonstrate myristoylation. 178 
Lipidation of the protein of interest shown by mass spectrometry, radiolabelling or well characterised 179 
chemical probes in the wild type parasite constitute the only methods for direct proof of 180 
N-myristoylation in the native context, whereas lipidation of an overexpressed construct is good 181 
evidence. Other data, based on co-expression of the protein with NMT in E. coli or the effects of 182 
mutagenesis on membrane localisation are merely suggestive of N-myristoylation. 183 
Protein myristoylation in Plasmodium species 184 
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Relatively little is known about which proteins are N-myristoylated in Plasmodium species. P. 185 
falciparum possesses a single NMT isoform (Gunaratne et al. 2000) which is able to transfer 186 
myristate from Myr-CoA to a peptide substrate based on PfARF1 (Gunaratne et al. 2000). 187 
Experimentally studied substrates have roles in life cycle regulation or progression (calcium 188 
dependent protein kinase 1 [CDPK1] and Calpain) (Moskes et al. 2004; Russo et al. 2009a; Russo et 189 
al. 2009b), host cell invasion (45 kDa glideosome associated protein [GAP45]) (Rees-Channer et al. 190 
2006), trafficking (ARF1) (Leber et al. 2009), Golgi function (GRASP1)  (Struck et al. 2005) and 191 
energy metabolism (Adenylate kinase 2, AK2) (Rahlfs et al. 2009). However, only GAP45 and 192 
CDPK1 have been shown to be N-myristoylated in their native context (Moskes et al. 2004; Rees-193 
Channer et al. 2006), whilst evidence for N-myristoylation of Calpain is based on radiolabelling of a 194 
Calpain-GFP construct (Russo et al. 2009a). For other potential targets such as Armadillo repeats only 195 
protein (ARO), AK2 and GRASP1, evidence is limited (Struck et al. 2005; Rahlfs et al. 2009; 196 
Cabrera et al. 2012). CDPK1 requires N-myristoylation for membrane localisation (Moskes et al. 197 
2004), and its gene cannot be knocked out in P. falciparum or the rodent parasite P. berghei, implying 198 
essentiality (Kato et al. 2008; Tewari et al. 2010). In addition, CDPK1 has key functions in multiple 199 
stages of the parasite life cycle and is involved in translational activation during sexual development 200 
(Sebastian et al. 2012). Another potentially myristoylated kinase, CDPK4, has been shown to be 201 
essential for sexual reproduction and mosquito transmission in P. berghei (Billker et al. 2004). 202 
GAP45 is an N-myristoylated protein with a direct role in parasite invasion of RBCs. It is localised at 203 
the inner membrane complex (IMC), a series of membrane structures lying beneath the parasite 204 
plasma membrane (PM) (Jones et al. 2006). An actomyosin motor, located between the IMC and the 205 
PM, drives merozoite invasion, allowing the parasite to enter the RBC (Baum et al. 2006). In 206 
Toxoplasma gondii, GAP45 is essential to the function of the motor, and therefore for host cell egress, 207 
motility and invasion: it has a role in the recruitment of the motor complex and there is evidence for a 208 
structural role in maintaining pellicle cohesion during invasion, presumably holding the IMC and PM 209 
together (Frenal et al. 2010). Recent data on the localisation of PfGAP45 and N- or C-terminal 210 
mutants are consistent with this role in spanning the IMC-PM gap (Ridzuan et al. 2012). 211 
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Protein myristoylation in Leishmania species 212 
As with Plasmodium, very few proteins have been experimentally validated as N-myristoylated in 213 
Leishmania species. Known NMT substrates include proteins involved in trafficking (ARL1 (Sahin et 214 
al. 2008)) and proteins of unknown function, such as HASPB, a member of a family of hydrophilic 215 
acylated surface proteins expressed in the host and required for parasite development in the insect 216 
vector (Denny et al. 2000; Sadlova et al. 2010). A family of ‘small myristoylated proteins’ with 217 
probable functions at the flagellum (Tull et al. 2004; Tull et al. 2012) and a protein phosphatase 218 
(PPEF) (Mills et al. 2007) have also been reported. In the related trypanosomatid parasites 219 
Trypanosoma brucei and T. cruzi, known likely substrates include TbARF1 (Price et al. 2007), 220 
TbARL1 (Price et al. 2005), TbARL6 (Price et al. 2012), cytoskeletal protein TbCAP5.5 (Hertz-221 
Fowler et al. 2001), which is involved in cell morphogenesis (Olego-Fernandez et al. 2009), a 222 
flagellar-localised protein (TcFCaBP) (Godsel and Engman 1999) and a metacaspase implicated in 223 
virulence (Proto et al. 2011). N-Myristoylation of native protein has only been demonstrated directly 224 
for LdSMP1 (Tull et al. 2004), TcFCaBP (Godsel and Engman 1999), TbCAP5.5 (Hertz-Fowler et al. 225 
2001) and TbARL6 (Price et al. 2012), but there is evidence for lipidation of LmPPEF (Mills et al. 226 
2007) and HASPB (Denny et al. 2000) in Leishmania. In all other cases evidence is limited. 227 
Myristoylation of LdARL1 is essential for localisation to the Golgi (Sahin et al. 2008) and ARL3, 228 
which is involved in maintaining the flagellum of promastigotes, is also thought to be myristoylated 229 
(Cuvillier et al. 2000). A number of other proteins have been shown to carry a dual acylation motif, 230 
including HASPB, which localises to the outer leaflet of the plasma membrane in infective stages 231 
(Denny et al. 2000). N-terminal N-myristoylation and internal S-palmitoylation are both required for 232 
this targeting. Similarly, SMP-1 is flagellum-targeted by myristoylation and palmitoylation (Tull et al. 233 
2004). A bioinformatic approach predicted around 60 N-myristoylated proteins in Leishmania (Mills 234 
et al. 2007), many of which are of unknown function and share little identity with other eukaryotic 235 
proteins, suggestive of parasite-specific roles.  236 
Current challenges in defining the N-myristoylated parasite proteome 237 
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The handful of identified NMT substrates reflects what is known in other organisms: that N-238 
myristoylation is involved in crucial cellular processes. However, a comprehensive understanding of 239 
the N-myristome and the roles of N-myristoylated proteins in protozoa, particularly in infective stages, 240 
is still lacking. This is partly due to technical limitations associated with these organisms – for 241 
example, challenges in the genetic manipulation of P. falciparum and L. donovani intracellular human 242 
infective stages, and a lack of functional analysis of many of the target proteins – but also because 243 
detecting lipidation of a native protein is inherently difficult. Radiolabelling with [3H]myristate or 244 
other fatty acids such as palmitate with detection by fluorography is the most common traditional 245 
method for studying protein acylation, but is a laborious process due to the very long (weeks or 246 
months) exposure times required.  Mass spectrometry is a powerful and continually advancing 247 
technique that can be used to detect PTMs such as fatty acylation, but generally the protein of interest 248 
must first be highly enriched and lipophilic fatty acylated proteins can be lost during preparation 249 
(Resh 2006b). The concentration range of proteins within cells is huge – around 5-6 orders of 250 
magnitude (Tyers and Mann 2003) – and this further hinders detection of rare proteins in complex 251 
mixtures. Chemical proteomic approaches have revolutionised the field of post-translational 252 
modification in the past decade, particularly for low abundance PTMs such as N-myristoylation. Acyl 253 
biotin exchange chemistry (ABE), where palmitate is exchanged site-specifically for biotin at the site 254 
of PTM (Roth et al. 2006), is widely used for analysing S-palmitoylation and was recently applied in 255 
P. falciparum blood stages with the identification of several thousand new potential targets (Jones et 256 
al. 2012). Another methodology, the bioorthogonal probe approach, involves the metabolic 257 
incorporation of a PTM substrate analogue containing a small, biologically inert chemical tag into 258 
proteins in live cells; the tag is subsequently functionalised with useful labels for detection or 259 
identification (Wright et al. 2010; Hang et al. 2011). These approaches have been used to great effect 260 
for the profiling of acylated proteins in mammalian cells and tagged lipid analogues were recently 261 
applied to identify S-palmitoylated proteins in P. falciparum (in parallel with ABE) (Jones et al. 2012) 262 
and to demonstrate N-myristoylation of T. brucei ARL6, a protein with a putative role in flagellum 263 
biogenesis (Price et al. 2012). Chemical probes have the potential to greatly expand the list of N-264 
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myristoylated proteins in parasitic protozoa and contribute to our understanding of NMT as a drug 265 
target. 266 
TOWARDS NMT INHIBITORS AS ANTIMALARIAL OR ANTILEISHMANIAL AGENTS  267 
Several lines of evidence suggest that NMT is a promising drug target for malaria and leishmaniasis; 268 
it is a monomeric enzyme carrying out a specific modification on substrates involved in diverse and 269 
essential pathways, it is essential for viability where genetic validation has been possible, and is 270 
constitutively expressed. Furthermore it is genetically and chemically validated as a drug target in T. 271 
brucei, where small molecule inhibitors have been shown to be effective in animal models (Frearson 272 
et al. 2010). The wide variety of NMT substrates may limit the potential for resistance to develop 273 
against inhibitors targeting the protein binding site, since mutations in this site could inhibit correct 274 
myristoylation of substrates. 275 
Initial research within our group focused on the discovery of plasmodial NMT inhibitors as chemical 276 
probes and potential therapeutic agents for the treatment of malaria, due to the availability of chemical 277 
starting points for this indication. Drug repositioning, the adaptation of an existing drug for a new 278 
indication, is often used to bypass the significant cost of clinical trials as the safety/pharmacokinetic 279 
data for these compounds has already been established (Sleigh and Barton 2010). A similar approach 280 
can be used for hit discovery (the “piggy-back approach”) to discover promising hit series without the 281 
cost of an HTS campaign (Gelb et al. 2003). In the case of NMT, a wealth of information has been 282 
collated with the purpose of generating antifungal NMT inhibitors. It was hypothesised that this 283 
information could be used as a valuable resource in the generation of parasitic NMT inhibitors, since 284 
CaNMT and PfNMT display 38% identity and 65% similarity.  285 
In the process of validation of a radioactive assay for monitoring N-myristoylation, a library of 43 286 
CaNMT inhibitors containing a benzothiazole scaffold (provided by Pfizer) were screened against 287 
PfNMT and Homo sapiens NMT1 (HsNMT1) (Bowyer et al. 2007). Of these 43 compounds, dose-288 
response curves were generated for 7 of the most promising inhibitors, four of which reduced 289 
parasitaemia in vitro. These compounds had weak enzyme affinity and cellular potency, and displayed 290 
Page 12 of 36Parasitology
For Peer Review
very high molecular weight and lipophilicity for compounds with this level of activity. Ligand 291 
Efficiency (LE) is a commonly-used measure of how tightly a compound binds to a target protein, 292 
relative to its overall size (Hopkins et al. 2004; Bembenek et al. 2009); LE > 0.35 is considered 293 
favourable, as it suggests scope for substantial optimisation. However, LE in this series was around 294 
0.21, limiting the potential for future development. A distinct small library of 25 previously described 295 
CaNMT and TbNMT inhibitors was also tested against PfNMT in vitro and compound RO-09-4609 296 
emerged as a promising hit compound, with weak but selective PfNMT affinity. This hit was 297 
optimised by iterative medicinal chemistry, resulting in a moderate affinity and highly selective 298 
compound Example 26 (Yu et al. 2012), representing a 100-fold affinity improvement over the initial 299 
hit (Fig. 5A). The binding mode of these compounds was validated in PvNMT (81% sequence identity 300 
to PfNMT), confirming the hypothesis that these compounds are competitive with the peptide 301 
substrate; however, LE (0.29) remained sub-optimal. A scaffold hopping approach was then applied 302 
to yield 2,3-benzothiophene Example 9 (Rackham et al. 2012), resulting in the most ligand efficient 303 
inhibitor discovered at this stage of development against PfNMT (Fig. 5A). Crystallography of this 304 
inhibitor series bound to PvNMT confirmed that the 2,3-benzothiophene inhibitors occupy a distinct 305 
binding mode to the 2,3,4 benzofurans exemplified by Example 26 (Yu et al. 2012), representing a 306 
novel inhibitor series for further development (Fig. 5B) (Rackham et al. 2012).  307 
Whilst the “piggy-back” approach provided a highly ligand-efficient series of PfNMT inhibitors, 308 
cross-screening the same set of compounds against L. major NMT failed to identify any starting 309 
points (Panethymitaki et al. 2006), necessitating alternative hit generation strategies. High-throughput 310 
screening has been successful in identifying multiple series of NMT inhibitors, including C. albicans 311 
(Masubuchi et al. 2001; Ohtsuka 2003), Aspergillus fumigatus (Bowyer et al. 2008), Cryptococcus 312 
neoformans (Bowyer et al. 2008) and T. brucei (Frearson et al. 2010). Although compounds from the 313 
latter publication have been co-crystallised with L. major NMT and display excellent enzyme affinity,  314 
the cellular potency of this series has not been disclosed. Consequently, we initiated a broader 315 
screening programme to identify additional selective inhibitors of Plasmodium and Leishmania 316 
NMTs. We screened the 150,000 compound Pfizer Global Diverse Representative Set against 317 
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LdNMT, anticipating that hits would be likely to possess pan-Leishmania NMT activity since the 318 
residues involved in the binding pocket are completely conserved (Brannigan et al. 2010). We also 319 
screened the same set against PfNMT, and the initial hit set was supplemented by analogues selected 320 
from the remainder of the Pfizer file (~ 2.5 million compounds at the time of the high-throughput 321 
screen) (Bell et al. 2012). In addition, a separate library of 60,000 compounds was screened against 322 
PvNMT, in collaboration with MRC Technology, in the hope of identifying distinct hit compounds 323 
(Goncalves et al. 2012a). 324 
Comparison of the hits from each HTS (Fig. 6) shows a remarkably wide range of structural features. 325 
Although many possess a basic centre, a common pharmacophore of several previously described 326 
NMT inhibitors, the hits feature primary, secondary and tertiary amines, which may be interacting 327 
with the conserved C-terminal Leu of the enzyme. However, the MRCT HTS hit (MRT00057965) is 328 
not basic and makes an alternative H-bond interaction with Ser319 (Goncalves et al. 2012b). Based on 329 
the diversity of known binding modes for NMT inhibitors, it is difficult to predict those for novel 330 
inhibitor series, and structures of the remaining HTS hits are, as yet, unreported. A limited medicinal 331 
chemistry optimization programme based on the MRT hit has been published (Goncalves et al. 332 
2012b), resulting in a confirmed hit with improved physical properties and moderate selectivity over 333 
the human isoforms. In order to address the enzyme selectivity issue, the Pfizer screen hit set was also 334 
tested in dose-response assays against both human NMT isoforms and against T. brucei NMT (Bell et 335 
al. 2012). Consistent with our previous findings, LdNMT seems distinct from the other NMTs in our 336 
screening panel, as most hits show excellent selectivity. In contrast, selectivity for PfNMT over either 337 
human NMT is more elusive, though the screen did identify two hit series with encouraging profiles.  338 
The structural basis for the observed selectivities remains unclear. Analysis of the peptide-binding 339 
pocket of LdNMT identified two residue differences with T.brucei NMT (Brannigan et al. 2010), and 340 
the same residues are also points of differentiation between  LdNMT and both human NMTs. In 341 
contrast, the residues lining the binding pocket are conserved between PfNMT and human NMT with 342 
the exception of a conservative F334Y change, which is also a point of difference between PfNMT 343 
and P.vivax NMT. Plasmodium/human NMT selectivity has been attributed to differences in their 344 
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ability to tolerate a conformational change in Y296 (HsNMT1 numbering) (Yu et al. 2012). It remains 345 
to be seen whether this difference in conformation is observed with other Plasmodium-selective 346 
inhibitors. 347 
FUTURE PERSPECTIVES 348 
Two significant hurdles remain for the validation of NMT as a drug target in malaria and 349 
leishmaniasis: the challenge of understanding the role of N-myristoylation through understanding of 350 
its downstream protein substrates, and proving its essentiality in clinically-relevant parasites.  351 
Protein N-myristoylation is a mechanism used universally by eukaryotes to direct protein localisation 352 
and hence function, but detecting protein lipidation by traditional methods presents challenges, 353 
particularly in P. falciparum and L. donovani which are not easily genetically manipulated and go 354 
through distinct life cycle stages in a variety of host environments. Bioinformatic prediction suggests 355 
that many proteins with diverse and unknown roles are likely to be myristoylated in parasitic 356 
protozoa, but in very few cases has acylation been experimentally validated. The development of new 357 
techniques to profile protein lipidation, such as the application of bioorthogonal chemical probes 358 
(Heal and Tate 2010), may allow us to gain a much wider and in-depth understanding of the 359 
myristoylated proteome and to explore the downstream effects of NMT inhibition in these important 360 
human pathogens. 361 
Demonstration of essentiality and druggability of NMT in P. falciparum and L. donovani requires 362 
selective inhibitors, and proof that these compounds act on-target in parasites. Progress towards 363 
selective and potent parasite NMT inhibitors is at an exciting stage; Example 9 (Fig. 5) derived from 364 
the “piggy-back” approach represents a promising starting point for inhibitor development, 365 
demonstrating excellent ligand efficiency and selectivity over the human orthologues. Future 366 
development of this series will focus on affinity enhancements whilst maintaining optimum 367 
physicochemical properties for drug-like molecules, with the aim of generating a high value lead 368 
series for clinical development. Replacement of the alkyl ester in Example 9 with a more biologically 369 
stable isostere is a paramount objective for further development since oral administration is a 370 
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prerequisite for a malaria medication. In addition, the other Plasmodium-selective hits identified (Fig. 371 
6) represent highly promising series for further development, demonstrating a range of chemotypes 372 
with varying physicochemical properties. Successful elaboration of any of these hit series into a 373 
potent, selective and drug-like inhibitor of NMT would enable investigation in cellular and in vivo 374 
models of malaria, providing a chemical tool for the validation of NMT as a drug target in malaria 375 
infections. The need for new drugs against leishmaniasis is still more pressing, particularly in view of 376 
the relatively neglected nature of this disease. Our recent screening initiative has also opened the door 377 
to the development of potent, selective inhibitors of Leishmania NMT, and we anticipate that the 378 
available chemical matter will enable both the development of tools to explore the role and 379 
importance of NMT in this challenging organism, and new starting points for discovery of 380 
antileishmanial drugs. 381 
The historic track record of targeted approaches to treatment of parasitic infections is in general 382 
relatively poor, since there are significant barriers to overcome in achieving good translation of 383 
enzyme to cellular activity and in vivo efficacy.  Future work in our laboratory is focused on 384 
overcoming these hurdles to confirm the relevance of NMT inhibition as a valid target for treating 385 
parasitic infections. 386 
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 FIG. LEGENDS 744 
Fig. 1: Structures of clinically-relevant antimalarial drugs. 745 
Fig. 2: Structures of clinically-relevant antileishmanial drugs. 746 
Fig. 3: The transfer of myristate from myristoyl-CoA to the N-terminal glycine residue of a target peptide (grey circles) by 747 
the enzyme N-myristoyltransferase (NMT). 748 
Fig. 4: A) Ternary co-crystal structure of ScNMT (grey surface) with bound peptide substrate (green) and a non-749 
hydrolysable myristoyl-CoA analogue (cyan) bound in the active site. PDB ID: 1IID, Farazi et al.(Farazi et al. 2001b). B) 750 
Myr-CoA or NHM from co-crystal structures with different NMTs; 4A95: NHM in PvNMT, green; 2WUU: NHM in 751 
LdNMT, cyan; 2P6E: Myr-CoA in ScNMT, yellow; 1IIC: Myr-CoA in ScNMT, purple; 3IWE: Myr-CoA in HsNMT1, 752 
orange; 1IYK: Myr-CoA in CaNMT, blue. Images generated using PyMOL (DeLano Scientific). 753 
Fig. 5: A) Summary of the PfNMT inhibitor series obtained by a “Piggy-Back” approach from fungal NMT inhibitor RO-754 
09-4609. B) Binding mode of Example 26 (Yu et al. 2012) bound to the Plasmodium vivax NMT active site. PDB 755 
Accession Code: 4B14. 756 
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Fig. 6: Structures of hits obtained by high throughput screening against protozoal NMTs 757 
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